Latest News for: Treatments for obesity

Edit

Leading Journal Unveils Groundbreaking Efficacy Of Novel Treatment For Obesity, Diabetes, And Liver Disease

MENA FN 18 Jan 2024
(MENAFN - GlobeNewsWire - Nasdaq) Durham, NC, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The publication of a landmark research paper demonstrates the exceptional efficacy of the ForePass– endoscopic device ... .
Edit

Leading Journal Unveils Groundbreaking Efficacy of Novel Treatment for Obesity, Diabetes, and ...

The Eagle-Tribune 18 Jan 2024
Dr Giorgio Castagneto Gissey, Keyron’s CEO, stated, "ForePass is a real breakthrough for high BMI individuals, for whom available treatment options are often ineffective or inappropriate.
Edit

Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity management

Market Watch 04 Jan 2024
OMGA, -8.08% and Cellarity on new treatments for obesity management ... R&D costs for each company ... MASH is a chronic liver disease with high unmet patient need for which there is currently no treatment.
Edit

How a vibrating pill could be the latest treatment for obesity

WPTV 02 Jan 2024
Engineers at the Massachusetts Institute of Technology (MIT) are shaking things up in the world of obesity treatments ... “For somebody who wants to lose weight or control their appetite, it could be taken before each meal,” said Dr.
Edit

New Treatment for Obesity Hits Pharmacy Shelves

Dispatch Argus 05 Dec 2023
Eli Lilly launched Zepbound, the latest product to join the exploding market for weight loss medications ....
Edit

New treatment for obesity to be covered by Japan's public insurance

Japan Times 21 Nov 2023
A new treatment for obesity will be covered by ...
Edit

Q and A with Dr. David Macklin: 'Treatment for obesity is meant to be long term'

Canoe 15 Nov 2023
'Treatment for obesity is meant to be long term' Back to video ... What are some effective treatments for people living with obesity? ... The treatment for obesity is meant to be long term, just like any ...
Edit

Carmot Therapeutics Highlights Clinical Data From Its Pipeline Of Treatments For Obesity And Diabetes At Obesityweek®

MENA FN 15 Oct 2023
(MENAFN - GlobeNewsWire - Nasdaq) – CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with ... .
Edit

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and ...

Enid News & Eagle 15 Oct 2023
Overall, these data support further clinical evaluation of CT-388, with higher doses while maintaining and exploring simpler titration schemes, for the treatment of obesity, T2D and other weight-related comorbidities.
Edit

It’s time for Congress to update Medicare to cover treatments for obesity

Longview News-Journal 14 Oct 2023
Medicare covers treatments for other chronic diseases, including diabetes, prediabetes, arthritis, heart disease, chronic kidney diseases, and hypertension, yet does not cover the full spectrum of care for obesity as a chronic disease.
Edit

Pfizer to advance oral candidate danuglipron as treatment for obesity and diabetes toward late-stage trial and discontinue lotiglipron

Market Watch 26 Jun 2023
PFE, -1.11% said Monday it’s planning to advance its oral candidate danuglipron toward late- stage development as a treatment for obesity and type 2 diabetes, but will discontinue development of a second candidate called lotiglipron.
Edit

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ...

Nasdaq Globe Newswire 24 Jun 2023
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a 4 week treatment period in overweight and obese otherwise healthy participants – ... .
Edit

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and ...

Nasdaq Globe Newswire 16 Jun 2023
The treatment combines SciSparc's Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide™, and Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions ... .
Edit

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Nasdaq Globe Newswire 16 Jun 2023
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™ ... .
Edit

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity ...

Eagle-Tribune 16 Jun 2023
... nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic syndrome.

Most Viewed

File - T-150K tractor on the field. Kasova Hora, Ivano-Frankivsk Oblast, Ukraine. Ukraine is the world's largest producer of sunflower oil and a major global producer of grain and sugar.
Creative Commons / Vian https://creativecommons.org/licenses/by-sa/4.0/deed.en
×